Immatics (IMTX) Stock Forecast, Price Target & Predictions
IMTX Stock Forecast
Immatics stock forecast is as follows: an average price target of $22.00 (represents a 80.77% upside from IMTX’s last price of $12.17) and
IMTX Price Target
Immatics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 16, 2024 | Graig Suvannavejh | Mizuho Securities | $16.00 | $11.08 | 44.40% | 31.47% |
| Aug 09, 2022 | Geulah Livshits | Chardan Capital | $28.00 | $12.43 | 125.26% | 130.07% |
The latest Immatics stock forecast, released on May 16, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $16.00, which represents a 44.40% increase from the stock price at the time of the forecast ($11.08), and a 31.47% increase from IMTX last price ($12.17).
Immatics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $16.00 |
| Last Closing Price | $12.17 | $12.17 | $12.17 |
| Upside/Downside | -100.00% | -100.00% | 31.47% |
In the current month, the average price target of Immatics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immatics's last price of $12.17. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Immatics Financial Forecast
Immatics Revenue Forecast
| Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $9.80M | $37.65M | $15.06M | $17.21M | $102.91M | $15.73M | $6.44M | $5.19M | $7.40M | $9.45M | $7.87M | $6.90M |
| Avg Forecast | $18.30M | $17.38M | $14.99M | $15.47M | $13.40M | $20.53M | $13.83M | $10.92M | $20.43M | $11.91M | $23.55M | $162.16M | $10.27M | $10.79M | $8.83M | $8.59M | $7.83M | $7.30M | $5.75M | $7.76M | $6.36M |
| High Forecast | $24.12M | $22.90M | $19.75M | $17.00M | $17.65M | $27.05M | $21.17M | $14.38M | $26.92M | $15.69M | $31.03M | $213.67M | $10.27M | $13.83M | $11.32M | $11.01M | $10.04M | $9.36M | $7.37M | $8.36M | $7.65M |
| Low Forecast | $15.03M | $14.27M | $12.31M | $13.94M | $11.00M | $16.86M | $6.49M | $8.96M | $16.78M | $9.78M | $19.34M | $133.16M | $10.27M | $8.08M | $6.61M | $6.43M | $5.86M | $5.47M | $4.30M | $6.89M | $4.07M |
| # Analysts | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.82% | 1.60% | 0.09% | 1.68% | 9.54% | 1.78% | 0.75% | 0.66% | 1.01% | 1.64% | 1.01% | 1.08% |
Immatics's average Quarter revenue forecast for Jun 23 based on 2 analysts is $20.43M, with a low forecast of $16.78M, and a high forecast of $26.92M. IMTX's average Quarter revenue forecast represents a 108.59% increase compared to the company's last Quarter revenue of $9.80M (Mar 23).
Immatics EBITDA Forecast
| Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-22.36M | $10.46M | $-19.44M | $-14.82M | $70.13M | $-15.33M | $-25.34M | $-22.50M | $-20.40M | $-21.53M | $-175.86M | $-17.64M |
| Avg Forecast | $-13.66M | $-12.97M | $-11.19M | $-11.55M | $-10.00M | $-15.32M | $-10.32M | $-8.15M | $-15.25M | $-8.89M | $-17.58M | $-121.03M | $-7.66M | $-8.05M | $-6.59M | $-6.41M | $-5.84M | $-5.45M | $-3.39M | $-2.94M | $-4.75M |
| High Forecast | $-11.22M | $-10.65M | $-9.19M | $-10.40M | $-8.21M | $-12.58M | $-4.85M | $-6.69M | $-12.52M | $-7.30M | $-14.44M | $-99.39M | $-7.66M | $-6.03M | $-4.94M | $-4.80M | $-4.38M | $-4.08M | $-3.22M | $-2.64M | $-3.04M |
| Low Forecast | $-18.00M | $-17.10M | $-14.74M | $-12.69M | $-13.18M | $-20.19M | $-15.80M | $-10.74M | $-20.10M | $-11.71M | $-23.16M | $-159.48M | $-7.66M | $-10.32M | $-8.45M | $-8.22M | $-7.49M | $-6.99M | $-3.53M | $-4.08M | $-5.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.52% | -0.60% | 0.16% | 1.93% | -8.71% | 2.33% | 3.96% | 3.85% | 3.74% | 6.35% | 59.72% | 3.72% |
2 analysts predict IMTX's average Quarter EBITDA for Mar 23 to be $-8.89M, with a high of $-7.30M and a low of $-11.71M. This is -184.93% lower than Immatics's previous annual EBITDA (Dec 22) of $10.46M.
Immatics Net Income Forecast
| Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | $-15.12M | $-13.26M | $-20.93M | $-13.98M | $85.66M | $-17.51M | $-31.41M | $-24.23M | $-19.36M | $-25.15M | $-335.43M | $-22.77M |
| Avg Forecast | $-30.25M | $-27.12M | $-38.19M | $-29.26M | $-29.05M | $-21.13M | $-33.06M | $-37.35M | $-25.36M | $-27.91M | $-7.70M | $206.11M | $-37.54M | $-26.79M | $-29.44M | $-26.99M | $-27.28M | $-22.15M | $-4.59M | $-3.99M | $-12.79M |
| High Forecast | $-23.21M | $-20.81M | $-29.31M | $-22.43M | $-22.29M | $-16.22M | $-26.61M | $-28.67M | $-19.46M | $-21.42M | $-5.91M | $291.23M | $-37.54M | $-18.05M | $-19.84M | $-18.19M | $-18.39M | $-14.93M | $-4.36M | $-3.58M | $-11.28M |
| Low Forecast | $-42.74M | $-38.31M | $-53.96M | $-36.08M | $-41.04M | $-29.85M | $-38.70M | $-52.78M | $-35.83M | $-39.43M | $-10.87M | $158.20M | $-37.54M | $-36.61M | $-40.24M | $-36.90M | $-37.29M | $-30.27M | $-4.79M | $-5.53M | $-15.80M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.54% | 1.72% | -0.10% | 0.37% | -3.20% | 0.59% | 1.16% | 0.89% | 0.87% | 5.47% | 84.03% | 1.78% |
Immatics's average Quarter net income forecast for Jun 22 is $-37.54M, with a range of $-37.54M to $-37.54M. IMTX's average Quarter net income forecast represents a -143.83% decrease compared to the company's last Quarter net income of $85.66M (Mar 22).
Immatics SG&A Forecast
| Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | $9.59M | $9.74M | $8.42M | $8.68M | $9.28M | $8.84M | $8.27M | $8.27M | $8.43M | $8.70M | $9.21M | $10.08M |
| Avg Forecast | $13.25M | $12.59M | $10.85M | $11.20M | $9.70M | $14.86M | $10.01M | $7.90M | $14.79M | $8.62M | $17.05M | $117.40M | $7.43M | $7.81M | $6.39M | $6.22M | $5.67M | $5.29M | $4.16M | $5.04M | $4.61M |
| High Forecast | $17.46M | $16.58M | $14.30M | $12.31M | $12.78M | $19.59M | $15.33M | $10.41M | $19.49M | $11.36M | $22.47M | $154.69M | $7.43M | $10.01M | $8.20M | $7.97M | $7.27M | $6.78M | $5.33M | $6.98M | $5.54M |
| Low Forecast | $10.88M | $10.33M | $8.91M | $10.09M | $7.97M | $12.21M | $4.70M | $6.49M | $12.15M | $7.08M | $14.00M | $96.41M | $7.43M | $5.85M | $4.79M | $4.66M | $4.25M | $3.96M | $3.12M | $4.51M | $2.95M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.11% | 0.57% | 0.07% | 1.17% | 1.19% | 1.38% | 1.33% | 1.46% | 1.60% | 2.09% | 1.83% | 2.19% |
Immatics's average Quarter SG&A projection for Jun 23 is $14.79M, based on 2 Wall Street analysts, with a range of $12.15M to $19.49M. The forecast indicates a 54.33% rise compared to IMTX last annual SG&A of $9.59M (Mar 23).
Immatics EPS Forecast
| Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.20 | $-0.20 | $-0.32 | $-0.22 | $1.36 | $-0.28 | $-0.50 | $-0.39 | $-0.31 | $-0.40 | $-5.33 | $-0.36 |
| Avg Forecast | $-0.29 | $-0.26 | $-0.37 | $-0.28 | $-0.28 | $-0.20 | $-0.32 | $-0.36 | $-0.25 | $-0.27 | $-0.07 | $2.00 | $-0.38 | $-0.32 | $-0.35 | $-0.32 | $-0.32 | $-0.26 | $-0.16 | $-0.23 | $-0.15 |
| High Forecast | $-0.23 | $-0.20 | $-0.28 | $-0.22 | $-0.22 | $-0.16 | $-0.26 | $-0.28 | $-0.19 | $-0.21 | $-0.06 | $2.83 | $-0.38 | $-0.21 | $-0.23 | $-0.21 | $-0.22 | $-0.18 | $-0.11 | $-0.22 | $-0.13 |
| Low Forecast | $-0.41 | $-0.37 | $-0.52 | $-0.35 | $-0.40 | $-0.29 | $-0.38 | $-0.51 | $-0.35 | $-0.38 | $-0.11 | $1.53 | $-0.38 | $-0.43 | $-0.48 | $-0.44 | $-0.44 | $-0.36 | $-0.22 | $-0.23 | $-0.19 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.74% | 2.68% | -0.16% | 0.58% | -4.30% | 0.81% | 1.57% | 1.21% | 1.18% | 2.52% | 23.62% | 2.38% |
According to 1 Wall Street analysts, Immatics's projected average Quarter EPS for Jun 22 is $-0.38, with a low estimate of $-0.38 and a high estimate of $-0.38. This represents a -127.96% decrease compared to IMTX previous annual EPS of $1.36 (Mar 22).
Immatics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ALXO | ALX Oncology | $2.18 | $24.50 | 1023.85% | Buy |
| KRON | Kronos Bio | $0.94 | $7.63 | 711.70% | Buy |
| LYEL | Lyell Immunopharma | $1.39 | $9.50 | 583.45% | Hold |
| AVTE | Aerovate Therapeutics | $1.91 | $13.00 | 580.63% | Hold |
| FENC | Fennec Pharmaceuticals | $5.26 | $15.75 | 199.43% | Buy |
| BCAB | BioAtla | $1.68 | $5.00 | 197.62% | Buy |
| EWTX | Edgewise Therapeutics | $18.08 | $48.00 | 165.49% | Buy |
| MLYS | Mineralys Therapeutics | $11.98 | $30.00 | 150.42% | Buy |
| REPL | Replimune Group | $11.03 | $24.20 | 119.40% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.06 | $36.00 | 99.34% | Buy |
| KROS | Keros Therapeutics | $55.04 | $105.00 | 90.77% | Buy |
| IMTX | Immatics | $12.17 | $22.00 | 80.77% | - |
| MRUS | Merus | $50.10 | $77.86 | 55.41% | Buy |
| CRNX | Crinetics Pharmaceuticals | $52.99 | $70.14 | 32.36% | Buy |
| HRMY | Harmony Biosciences | $38.81 | $50.67 | 30.56% | Buy |
| JANX | Janux Therapeutics | $49.46 | $59.25 | 19.79% | Buy |
IMTX Forecast FAQ
Will Immatics stock go up soon?
According to Wall Street analysts' prediction for IMTX stock, the company can go up by 80.77% (from the last price of $12.17 to the average price target of $22), up by 130.07% based on the highest stock price target, and up by 31.47% based on the lowest stock price target.
Can Immatics stock reach $20?
IMTX's average twelve months analyst stock price target of $22 supports the claim that Immatics can reach $20 in the near future.
What are Immatics's analysts' financial forecasts?
Immatics's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $57.09M (high $78.17M, low $42.01M), average EBITDA is $-42.609M (high $-31.359M, low $-58.341M), average net income is $-124M (high $-96.159M, low $-167M), average SG&A $41.33M (high $56.59M, low $30.42M), and average EPS is $-1.2 (high $-0.933, low $-1.618). IMTX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $64.38M (high $81.46M, low $54.1M), average EBITDA is $-48.056M (high $-40.383M, low $-60.797M), average net income is $-118M (high $-90.252M, low $-161M), average SG&A $46.61M (high $58.97M, low $39.17M), and average EPS is $-1.141 (high $-0.876, low $-1.561).
Did the IMTX's actual financial results beat the analysts' financial forecasts?
Based on Immatics's last annual report (Dec 2022), the company's revenue was $172.83M, which missed the average analysts forecast of $206.76M by -16.41%. Apple's EBITDA was $46.34M, missing the average prediction of $-154M by -130.03%. The company's net income was $37.51M, missing the average estimation of $134.09M by -72.02%. Apple's SG&A was $36.12M, missing the average forecast of $149.7M by -75.87%. Lastly, the company's EPS was $0.56, missing the average prediction of $1.23 by -54.41%. In terms of the last quarterly report (Mar 2023), Immatics's revenue was $9.8M, missing the average analysts' forecast of $11.91M by -17.74%. The company's EBITDA was $-22.365M, beating the average prediction of $-8.888M by 151.63%. Immatics's net income was $-15.123M, missing the average estimation of $-27.907M by -45.81%. The company's SG&A was $9.59M, beating the average forecast of $8.62M by 11.18%. Lastly, the company's EPS was $-0.2, missing the average prediction of $-0.271 by -26.13%